CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Down 13.5% in February

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 127,800 shares, a decline of 13.5% from the February 13th total of 147,800 shares. Based on an average trading volume of 199,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.2% of the shares of the stock are sold short.

CytoMed Therapeutics Stock Up 2.4 %

GDTC stock traded up $0.06 during mid-day trading on Wednesday, reaching $2.69. The company’s stock had a trading volume of 241 shares, compared to its average volume of 75,326. The company’s 50 day moving average is $2.61 and its two-hundred day moving average is $2.38. CytoMed Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $4.05.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.